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Abstract
Background: Pharmacological intervention is essential for managing the symptoms of Parkinson’s disease.
Adherence to medication regimens however is a major problem. Poor adherence leads to significant motor
deterioration and inadequate symptom control. This results in poor quality of life. Whilst interventions to improve
medication adherence have shown considerable benefit in other chronic conditions, the efficacy of such
treatments in Parkinson’s disease is less well researched. Many people with Parkinson’s disease require substantial
support from spouse/caregivers. This often extends to medication taking. Consequently, spouse/caregiver’s support
for timely medication management is paramount. We aim to investigate the benefit of a novel intervention, Carer
Assisted Adherence Therapy, for improving medication adherence and quality of life in people with Parkinson’s
disease. Adherence therapy may help to optimise the efficacy of anti-parkinsonian agents, subsequently improving
clinical outcomes.
Methods/Design: A parallel, randomised controlled trial will be conducted to investigate whether carer assisted
adherence therapy is effective for improving medication adherence and quality of life. We aim to recruit 40
patient/carer pairs into each group. Participants will be randomly assigned by the Clinical Research Trials Unit at
the University of East Anglia. Adherence therapy is a brief cognitive-behavioural approach aimed at facilitating a
process of shared decision making. The central theory is that when patients make shared choices with a
professional they are more likely to continue with those choices because they are personally owned and
meaningful. Outcomes will be rates of adherence and quality of life, determined by the Morisky Medication
Adherence Scale-4 and the Parkinson’s disease Questionnaire-39 respectively. Assessments will take place post
randomisation, immediately post intervention and 12-weeks post randomisation. Primary outcomes are adherence
and quality of life at 12-week follow-up. Efficacy will be determined using intention-to-treat analysis. Independent
samples t-tests will compare mean changes between groups from baseline to follow-up. Per protocol analysis will
be conducted based on individuals with no major protocol deviation. Where imbalances in baseline characteristics
are identified, an adjusted analysis will be performed using a regression model. Analysis will be masked to
treatment allocation.
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Background
Parkinson’s disease
Parkinson’s disease (PD) is a progressive, disabling, neu-
rodegenerative disease that significantly reduces quality
of life (QoL) [1,2]. Debilitating symptoms of bradykine-
sia (slowness of movement), resting tremor, rigidity and
postural instability are principal features of PD [1,3]. In
addition to these motor symptoms, non-motor symp-
toms (NMS) such as cognitive impairment, dementia,
sleep disturbances, depression and falls are significantly
associated with reduced QoL [4]. Cognitive impairment
is reported to affect 20-30% of patients with PD, even in
the early stages of the disease [5]. As PD progresses cog-
nitive decline persists and patients may develop demen-
tia [6]. The cumulative prevalence has been reported to
be substantial; at least 75% of people with PD who sur-
vive longer than 10 years will develop dementia [6]. As
motor and NMS have considerable impact on QoL in
PD, addressing both is therefore an integral part of
management.
Treatment & Regimen Complexity
The pharmacological management of PD is complex.
Monoamine Oxidase-B (MAO-B) inhibitors, dopamine
receptor agonists and Levodopa represent first line
treatment options [1]. Typically younger individuals are
treated with a MAO-B inhibitor (one daily dose), espe-
cially if symptoms are mild, or a dopamine receptor
agonist (three daily doses) as first line intervention.
Older (≥ 75 years) individuals, especially those with or
at risk of cognitive impairment, may be treated with
Levodopa as first line therapy [7,8]. Although manage-
ment in early disease is usually adequate with mono-
therapy [7,8], more than half of people with PD take
two to four anti-parkinsonian medications three to four
times daily [9,10]. This is because multiple drug classes
are warranted as PD progresses [11-14]. Furthermore,
each drug may have different dosing schedules, further
complicating regimens [9]. Catechol-O-Methyltransfer-
ase inhibitors can supplement Levodopa adding further
complexity. Increasing doses and/or dosage frequency
may also be required to adequately manage worsening
symptoms in advanced stages [14]. With advancing dis-
ease, the therapeutic window narrows and becomes reli-
ant on more frequent and specific interval dosing to
maintain adequate treatment effect and avoid motor
fluctuations [7,15]. Some people with advanced PD can
take as many as ten doses a day in order to manage
fluctuations [8,16]. Dyskinesias (involuntary movements)
associated with long-term Levodopa use may also
require remediation in later PD [16]. Additionally, speci-
fic non-motor complications necessitate further drug
use [4,14].
Medication Non-adherence
To achieve optimal symptom control, adherence to
medication in PD is paramount [17]. However, it has
been reported that a third to half of all medicines pre-
scribed to people with long-term conditions are not
taken as recommended [18-20]. Therefore, not surpris-
ingly medication adherence is poor in people with PD,
especially as symptoms of cognitive impairment and
anxiety and depression have been reported to be highly
prevalent and which impact negatively on medication
adherence in this patient population [21]. Reported
medication adherence in PD was as low as 10% in one
study with 76% acknowledging miss-timed or missed
doses [22]. For drugs requiring multiple daily doses,
researchers reported only 3% fully adhered to medica-
tion regimens [23]. These findings suggest medication
non-adherence is significant in people with PD. The
consequences of non-adherence are substantial [24].
Poor adherence can result in wearing off of the treat-
ment effect which can significantly increase motor dys-
function [15]. People with PD may also over-medicate
with dopaminergic therapy [23]. This can result in
severe dyskinesia, potentially lead to the development of
impulse control disorder, especially when dopamine
receptor agonists are used, and may even result in psy-
chosis [25]. Dyskinesias have been associated with signif-
icant reductions in QoL [26].
Carer Involvement
Although people may be completely independent in the
early stages of PD, in advanced stages people usually
require considerable support with daily activities [27].
Many people with PD receive support through informal
carers such as a spouse or family member. This often
extends to medication management, particularly aiding
in the taking of medications [16,28]. For the caregiver,
the responsibility for and help with timely management
of a relative’s anti-parkinsonian medication is essential
[27].
Study Rationale
There is a need for an intervention that enhances adher-
ence to prescribed medication in PD. A targeted therapy
is likely to be associated with overall improvement in
rates of adherence, leading to optimal symptom control.
Increasing motor fluctuations and dyskinesias resulting
in disability have been associated with poor QoL [26].
As common motor symptoms of bradykinesia and rigid-
ity are sensitive to anti-parkinsonian therapies [8],
improved adherence to anti-parkinsonian medication
may facilitate a mechanism for improving QoL.
Interventions aiming to improve adherence have
demonstrated efficacy in other long-term conditions
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such as hypertension and psychotic disorders [29-32].
However, there is a paucity of evidence testing the effi-
cacy of adherence interventions in PD. Previous research
has identified a variety of factors that influence non-
adherence in PD: problems with complex treatment
regimens, polypharmacy, cognitive impairment and
depressive symptoms [15,16,33,34]. Therefore, a patient
centred therapy aimed at exploring personally relevant
benefits of medication use, formulating problem solving
strategies and exploring beliefs and concerns about
medications may improve adherence to anti-parkinso-
nian drugs. It is also acknowledged that in PD caregiver
involvement in fostering medication adherence can be
substantial [16]. This is essential where significant cog-
nitive impairment presents. Therefore, caregivers need
to be supported in their role of encouraging medication
adherence.
We hypothesise that an adherence therapy that targets
both people with PD and their spouse/carer is likely to
improve medication adherence and be associated with
better QoL compared to treatment as usual.
Methods/Design
Trial Design
A parallel group, randomised controlled trial will be
conducted to compare Carer Assisted Adherence Ther-
apy (CAAT-PARK) with Treatment as Usual (TAU) for
non-adherent people with PD and their spouse/carers.
The study will compare the two groups immediately
post intervention and at 12 weeks post randomisation
(follow-up).
Trial Objectives
To investigate whether people with PD and their
spouses/carer who receive a programme of CAAT-
PARK in addition to TAU show significantly greater
rates of medication adherence and improved QoL from
baseline to 12 week post randomisation compared to
those who receive TAU only.
Secondary objectives are to investigate whether people
who receive CAAT-PARK and those who receive TAU
differ in terms of overall disease state, activities of daily
living (ADL), beliefs about medication, generic health
related QoL, and levels of carer distress. We will investi-
gate whether baseline levels of cognitive impairment and
anxiety and depression influence the effective uptake of
CAAT-PARK. We also aim to investigate the experience
of those receiving the intervention.
Outcome Measures
Primary outcomes
• Change in adherence to medication determined by
the Morisky Medication Adherence Scale (MMAS-4)
[35]
• Change in QoL determined by the Parkinson’s Dis-
ease Questionnaire-39 (PDQ-39) [36]
Secondary outcomes
People with PD:
• Movement Disorder Society - Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS) Part I (non-motor
experiences of daily living), Part II (motor experiences
of daily living) and Part IV (motor complications) [37]
• Beliefs about Medication Questionnaire (BMQ) [38]
• EuroQol quality of life questionnaire (EQ-5D) [39]
Spouse/Carer Outcomes:
• Carer Distress Scale (CDS) [40]
• BMQ
Trial Participants
People attending Medicine for the Elderly or Neurology
outpatient appointments at a University Hospital in the
East of England, UK, for diagnosed or probable PD.
Spouse/carers will be invited to participate.
Inclusion Criteria
1. Adults diagnosed with, or with probable, Idiopathic
PD (three out of four of the chief UK Brain Bank
criteria).
2. Prescribed one or more anti-parkinsonian medica-
tions by a Consultant Neurologist or Consultant Physi-
cian with specialist knowledge of movement disorders.
3. English speaking and literate (participants are
required to actively engage in the therapy process).
4. Stable medication regime i.e. not altered within the
previous month and not expected to change during the
period of the research project (12 weeks).
5. Not demented or significantly cognitively impaired.
The clinical team will judge whether the patient has the
cognitive capacity required to participate fully in the
trial i.e. read patient information, complete self report
questionnaires and engage actively in the therapy
process.
6. Show poor adherence as determined by a MMAS-4
score ≥ 2.
Exclusion Criteria
1. Suspected Parkinsonism due to other causes than
idiopathic PD.
2. Treated with anti-parkinsonian medications for a
mental health complaint.
3. Diagnosed with dementia.
4. Life expectancy < 6 months.
Recruitment
People who are potentially eligible based on inclusion
criteria 1, 2, 3, 4 and 5 will be identified by the clinical
team two weeks prior to upcoming outpatient appoint-
ments. An information pack containing: a patient
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invitation letter, participant information sheet, MMAS-4
and a consent form for the MMAS-4 will be posted out
to those who are potentially eligible. This represents
stage one consent i.e. willingness to consider study par-
ticipation. An information sheet for the spouse/carer
will supplement the patient information. Patients will be
asked to return the MMAS-4 and the accompanying
consent form. People scoring ≥ 2 will be informed by
phone of their suitability to participate. Individuals who
are willing to participate but do not meet eligibility cri-
teria will be thanked for their interest. Eligible patients
will be approached for their consent to participate in
the trial on the day they attend clinic for their out-
patient appointment (stage two consent). Recruitment
will be a rolling programme over 12 - 14 months until
recruitment targets are achieved. Figure 1 shows the
CONSORT diagram for progression of participants
throughout the study duration.
Informed Consent
Thirty minutes will be set aside for taking informed
consent to ensure patients/carers possess a sound
understanding of the trial. At each point of participant
contact ongoing verbal consent will be sought. If
patients withdraw they will then receive standard care
(TAU). Data collected to the point of withdrawal will be
retained in the trial data set.
Randomisation
Participants will be randomly assigned to CAAT-PARK
or TAU. Randomisation will take place in a private
room following signed informed consent and comple-
tion of baseline (pre-randomisation) measures. Rando-
misation will be completed using computer generated
random numbers accessed via a web-based randomisa-
tion system developed by the Clinical Research Trials
Unit (CRTU) at the University of East Anglia (UEA).
Participants will be allocated a unique identifier number
which will be sent to CRTU where allocation will be
undertaken by permuted random blocks of four and six.
Participants will be stratified into spouse/carer present
or no spouse/carer present groups at randomisation
respectively in order to investigate the potential effect
modification of the spouse/carer on the treatment effect.
The trial medical statistician (ABC) assisting in the ana-
lysis of all study data will be masked to participant
group allocation.
Baseline Assessments
Once the patient has consented some of the baseline
data will be collected prior to randomisation. Baseline
measures for primary outcomes (MMAS-4, PDQ-39)
will be completed by participants at this stage to ensure
data is acquired prior to randomisation. Participants will
also be assessed in clinic prior to randomisation using
measures that cannot be self-reported and require a
rater, MDS-UPDRS parts I & IV and the Montreal Cog-
nitive Assessment (MoCA). The Hospital Anxiety &
Depression Scale (HADS) will also be completed at this
stage. All scales will be completed in a private consulta-
tion room. Participants will be instructed how to com-
plete all other baseline measures for secondary
outcomes before taking them home to complete in their
own time: BMQ, EQ-5D and MDS-UPDRS part II
(patient questionnaire). Spouse/carers will take the base-
line BMQ and CDS home to complete. Participants will
be asked to return these self-reported questionnaires
within two weeks of randomisation. The following infor-
mation will be obtained:
Description of Primary Measures
Morisky Medication Adherence Scale (MMAS-4)
The MMAS-4 is a self-report scale for identifying medi-
cation non-adherence [35] and has been used in PD
[16,41]. The scale is constructed of four items answered
by ‘yes’ or ‘no’. Four ‘no’ responses signifies perfect
adherence. Any ‘yes’ responses indicates some degree of
non-adherence with medication. We aim to recruit peo-
ple scoring two or more ‘yes’ responses.
Parkinson’s Disease Questionnaire - 39 (PDQ-39)
The PDQ-39 is a PD-specific QoL questionnaire. The
scale has been extensively tested for reliability and valid-
ity and is widely used in both research and clinical prac-
tice [42,43]. Items making up the scale measure eight
dimensions of health which are related specifically to
PD: mobility, ADL, emotional wellbeing, stigma, social
support, cognition, communication and bodily
discomfort.
Description of Secondary Measures
Movement Disorder Society - Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS)
The MDS-UPDRS is a revised version of the Unified
Parkinson’s Disease Rating Scale [37,44]. The MDS-
UPDRS has four parts of which we will use three,
namely, (I) Non-motor Experiences of Daily Living; (II)
Motor Experiences of Daily Living; (IV) Motor Compli-
cations. This represents 32 items from the scale. Twenty
questions are completed by the patient/caregiver as part
of a questionnaire and 12 questions are completed by
the assessor through a structured interview format - 6
items in part I and IV, respectively. When tested for its
clinimetric properties, the scale has been shown to have
high internal consistency, reliability and validity, and
correlates well with the original UPDRS [44]. Compe-
tency based training and an online examination devel-
oped by the Movement Disorders Society have been
completed by the Chief Investigator.
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Beliefs about Medication Questionnaire (BMQ)
The BMQ is comprised of two scales: (1) an 11 item
questionnaire relating to prescribed medication, (2) an 8
item questionnaire relating to general views about taking
medication. The questionnaires assess beliefs about the
necessity of prescribed medication for controlling illness
and concerns about taking medications [38]. Respon-
dents rate each item on a five point Likert-type scale
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility by 
clinical team 2 weeks before 
out-patient appointment 
Study information posted 
out to potential participants 
Patients return MMAS-4 
and initial consent form  
Scoring ?2 on the MMAS-
4 - informed of study 
suitability  
Patients see DJD after routine 
out-patient appointment to 
discuss study 
Baseline outcomes taken 
after signed informed 
consent 
Participants randomised to 
CAAT-PARK or TAU  
Allocated intervention: 
Participants receive 7 weekly 
sessions of CAAT-PARK  
Allocated TAU: 
Continue to receive usual 
care 
Follow-up:  
Immediately post 
intervention (Week 7-8) 
Follow-up: 
Week 7 
12 week Follow-up:  12 week Follow-up:  
Analysis of all study outcomes 
Figure 1 CONSORT diagram - progression through CAAT-PARK.
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depending on their degree of agreement (1 strongly dis-
agree, 5 strongly agree). Higher scores indicate higher
levels of concern or strong beliefs towards the use of
medication.
EuroQoL (EQ-5D)
The EQ-5D is an established, standardised generic
health utility index tool used extensively in clinical stu-
dies [39]. It consists of five items covering mobility, self-
care, usual activity, pain/discomfort, and anxiety/depres-
sion domains. A visual analogue scale represents one
final characteristic of the instrument. It provides a sim-
ple descriptive profile and can be used to estimate a sin-
gle index value for a respondent’s health status and
change in Quality Adjusted Life Years (QALYs).
Caregiving Distress Scale (CDS)
The CDS is a concise measure designed to assess and
profile informal caregivers with respect to stressful out-
comes. The scale was developed in a PD population
from various caregiving measures including a wide
range of items and varying associations with distress
[28,40]. The CDS comprises five distinct dimensions
comprising 17 items that have a potential negative
impact on caregivers. Answers are provided on a 0-4
scale based on level of agreement.
Satisfaction Questionnaire
To investigate patient and spouse/carer satisfaction with
the CAAT-PARK process, we will post out a satisfaction
questionnaire with the follow-up (week 12) outcome
measures.
Description of Other Measures (Prognostic Factors)
Montreal Cognitive Assessment Scale (MoCA)
The MoCA is a 30-point scale delivered by a rater.
The MoCA covers a range of executive functions and
has been proposed to be the most appropriate scale for
assessing cognitive impairment in PD research where
cognition is not the primary outcome [45]. The MoCA
has six orientation questions and a five word memory
recall task. A clock drawing task and a cube copy test
assess visuospatial function. Attention/concentration is
assessed using serial 7’s, target mapping and digit span
forward and backwards tasks. Executive functions are
evaluated using a shortened version of the Trial Mak-
ing B Test, phonemic fluency, and a verbal abstraction
task.
Hospital Anxiety and Depression Scale (HADS)
The HADS is a self screening questionnaire for anxiety
and depression [46]. The HADS consists of 14 ques-
tions, seven for each anxiety and depression and has
been widely used and validated [47].
In addition to levels of anxiety/depression and cogni-
tive capacity, we will identify and present demographics
at baseline: participants’ age, duration and severity of
PD (Hoehn & Yahr score), medication profile (type of
medications, dosage level and frequency), socioeconomic
status, co-morbidities, level of education and whether
medication is self-administered or given by a spouse/
carer.
Follow-up Measurements
Baseline measures assessed to determine the efficacy of
CAAT-PARK will be repeated immediately post inter-
vention and at 12-weeks post randomisation (follow-up)
(Figure 2). For the control group receiving TAU, assess-
ments will be at week seven and week twelve. For the
CAAT-PARK group, post intervention assessments will
be at week seven or eight and then at week 12. This
additional week at the midway post intervention time
Randomisation/ Baseline           Post-intervention           Follow-up
                                                                                                        
                                                           Week   7    or   8                                      Week 12 
T. arm 
C. arm 
 
12 Weeks 
T.arm: Treatment arm; C.arm: Control arm 
Figure 2 Study Design - assessment time points.
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point accommodates potential sickness or time away
providing flexibility from a pragmatic perspective.
Intervention
Description of Adherence Therapy
CAAT-PARK is a brief, cognitive-behavioural approach
aimed at facilitating a process of shared decision making
[29,48]. CAAT-PARK is rooted in the observation that a
person’s beliefs impact on treatment adherence. The
central theory is that when people make shared choices
with a professional they are more likely to continue with
those choices because they are personally owned and
meaningful [30]. Identification and amplification of the
personally relevant benefits of treatment, modifying
beliefs about medication and exploring ambivalence
towards medication taking behaviour represent interre-
lated constructs that are central tenants of the therapy.
CAAT-PARK is delivered in five phases that form the
core of the therapy (Figure 3): assessment, medication
problem-solving, a medication timeline (looking back),
exploring ambivalence, and discussing beliefs and con-
cerns about medication. Key therapy skills incorporate
exchanging information, developing discrepancy between
the patient’s thoughts and behaviours about medication,
socratic style questioning and working with resistance to
discussing medication and treatment. The aim of
CAAT-PARK is to achieve a mutual, informed decision
about medication between the individual and therapist.
A key concept is that where patients and therapists
make choices about treatment mutually, adherence to
that regimen will be enhanced [48,49].
Participants allocated to CAAT-PARK will receive
seven 30 minute sessions at weekly intervals. Assess-
ment and problem solving will be delivered twice, mak-
ing up seven sessions in total. Each weekly session will
incorporate a separate theme, however, each session will
be participant centred. Where a patient’s carer has con-
sented to the trial, the intervention will be delivered to
the carer at the same time. Ten sessions over the course
of the trial will be recorded to determine treatment fide-
lity against the CAAT-PARK manual [49].
Treatment as Usual
Participants randomised to TAU will receive no addi-
tional information regarding medication adherence. Care
will continue as usual according to routine practice. We
will not provide any guidance to the clinical team as to
the content of the usual care. Routinely usual care con-
stitutes a clinic visit every 9-12 months to see the hospi-
tal consultant who is managing the patient’s PD.
Adherence Assessment 
Five Key Phases: 
 
Assessment 
Problem Solving 
Looking Back 
Exploring Ambivalence 
Discussing beliefs/ concerns 
Key Skills: 
 
Focus on personal benefit 
Develop discrepancy 
Reduce resistance 
Socratic questioning 
Exchanging information  
 
Adherence Assessment 
Figure 3 CAAT-PARK model.
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Neurology specialist nurses may also see patients for
routine follow-up between consultant clinics.
Adverse Event Monitoring
Adverse events (AE) will be determined at each weekly
visit and will commence from the point of randomisa-
tion up to week 12 follow-up. An AE checklist was
developed following consensus views of the Trial Steer-
ing Committee (TSC) and medical specialists. AEs will
be reported to the TSC and the participants’ clinical
team for appropriate action. All AEs will be addressed
according to local Standard Operating Procedures
(SOPs) for clinical trials of non-Investigational Medic-
inal Products (non-IMPs) developed in accordance with
the Medicines for Human Use Regulations (2004) and
the Department of Health’s Research Governance Fra-
mework for Health and Social Care for identifying,
recording, and reporting adverse events in clinical trials.
Analysis
Baseline Analyses
To assess external validity, demographic, and clinical
characteristics of study participants’, responses at base-
line will be compared for participants who are subse-
quently randomised and participants who are screened
but not randomised. The specific criteria by which parti-
cipants are excluded from randomisation will be tabu-
lated. Demographic and clinical characteristics will be
compared between CAAT-PARK and TAU groups to
identify potential imbalances not accounted for by
randomisation.
Efficacy Analysis of Primary Outcomes
The efficacy of CAAT-PARK will be determined by
comparing the mean change in values of the two groups
from baseline to week 12 follow-up. Analysis between
the two groups will be made using an independent sam-
ple t-test. Intention to treat (ITT) and per protocol (PP)
analyses will be undertaken. For the intervention group,
this is irrespective of their compliance with CAAT-
PARK. ITT analysis will represent the primary analysis
and will be used for evaluation of all outcomes. PP ana-
lysis will include patients who comply with the treat-
ment as defined by completing five or more out of
seven CAAT-PARK sessions. All participants will
undergo sub-group analysis testing for potential effect
modification for the presence of a spouse/carer on the
treatment effect. Appropriate adjustments will be made
in the statistical analyses for potential factors that are
unevenly distributed between the groups. Specifically,
participants with significantly high reported levels of
cognitive impairment and anxiety and depression at
baseline (assessed with the MoCA and HADS, respec-
tively) will be analysed to determine the independent
impact of these prognostic factors on the treatment
effect. Adjusted estimates will be obtained by identifying
baseline imbalances and incorporating these into a
regression model using pre and post intervention pri-
mary outcome scores.
If normal distribution assumptions are not met, even
after suitable transformations, non-parametric analysis
will be adopted. Imputation for missing/incomplete data
will be carried out using chained equations with all out-
come measures and potentially correlated baseline
values. A total of 10 imputed datasets will be created.
Sample Size
We will recruit a total of ninety-two family units (patient/
carer pairs or patients alone), 46 per treatment group.
This includes an additional 15% (n = 6) for potential par-
ticipant attrition in each group. Where possible we aim
to recruit patients with a spouse/carer, however, we will
not exclude patient participants who do not have a
spouse/carer but are wishing to participate. Using the
primary outcomes, a pragmatic sample size of 40 partici-
pants per treatment group would provide an alpha of
0.05 and an 81% power to detect a difference of 25%
improvement in medication adherence in the interven-
tion group (detected by a one point shift in the MMAS-
4) against 0% in the control group. This also provides
80% power to detect a Cohen’s effect size of 0.69 in the
PDQ-39, based on the published standard deviation of
8.89 in this patient group [43]. This would allow a differ-
ence in means of 6.13 (8.89 × 0.69) units in the PDQ-39.
Qualitative Evaluation
Semi-structured interviews will be undertaken with a pur-
posively selected sub-sample of patients (n = 10) and
carers (n = 10) to explore the process and experience of
receiving CAAT-PARK. Participants wishing to be inter-
viewed will be pooled together and selected at random.
This will ensure identification of participants wanting to
be interviewed whilst preventing selection bias. Interviews
will be thirty minutes in duration. The aims are to illumi-
nate the quantitative findings by obtaining insight into the
experience of receiving CAAT-PARK; consider which ele-
ments of CAAT-PARK are most helpful; explore percep-
tions of how CAAT-PARK has influenced medication
taking; uncover potential barriers to receiving CAAT-
PARK and explore how CAAT-PARK could be enhanced.
All interview data will be audio recorded and transcribed
verbatim. The transcripts will be coded using thematic
analysis [50]. Analysis aims to ultimately inform the study
outcome of patient acceptability of CAAT-PARK.
Ethical Considerations
Although we do not anticipate any risk to study partici-
pants, we acknowledge the small possibility that
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increased medication adherence in PD may lead to
greater incidence of dyskinesia. Dyskinesia is a common
motor complication resulting from dopaminergic ther-
apy in PD and will therefore be monitored by the TSC.
It is theoretically possible that greater medication adher-
ence may trigger drug induced psychosis, a rare but
important complication of dopaminergic therapy in PD,
so this will also be monitored in all participants receiv-
ing CAAT-PARK for its potential development.
The trial protocol and all related documents were
given a favourable ethical opinion by Cambridge Central
NHS Research Ethics Committee (REC reference num-
ber: 11/EE/0179).
Discussion
Many people with PD do not take their anti-parkinso-
nian medications as prescribed. Sub-optimal adherence
to prescribed medication in people with PD results in
poor symptom control. This considerably impacts on
QoL. Previous research has reported the benefit of var-
ious interventions including adherence therapy for
improving medication adherence in other long-term
conditions. Through the use of CAAT-PARK we aim to
improve adherence behaviour in people with PD who
are non-adherent to their prescribed medication.
Furthermore, we aim to examine whether CAAT-PARK
is effective for improving QoL in this patient group.
We have recently reported the effectiveness of adher-
ence therapy in a trial of 136 hypertensive patients [51].
Improvements in medication adherence resulted in a
substantial reduction in both systolic and diastolic blood
pressures. Researchers have also tested the efficacy of
other adherence intervention programmes in patients
with psychotic disorders. One study showed people with
psychotic symptoms in schizophrenia significantly
improved after receiving a programme of adherence
therapy [52]. Findings have shown similar adherence
therapy interventions to provide direct benefit regarding
service engagement and medication adherence [53].
Moreover, patient attitudes towards and satisfaction
with medication improved in those who received treat-
ment adherence therapy [53]. Such positive findings
offer preliminary evidence of efficacy for the use of
adherence interventions in people with long-term condi-
tions and, furthermore, highlight patient acceptability of
therapeutic adherence programmes.
Despite supportive findings, there is a paucity of ran-
domised controlled trial evidence investigating the effi-
cacy of interventions for improving medication
adherence in people with PD. Findings from one study
showed a 13% significant difference in timing adherence
pre to post intervention between study groups after
receiving simple didactic information relating to the
continuous dopaminergic theory [54]. A recent study
used a standardised eight week educational programme
delivered to people with PD and their carers aiming to
address psychosocial issues [55]. Findings showed an
improvement in mood and less psychosocial problems
and need for help in primary caregivers after receiving
the intervention. Additionally patients improved in
mood; however, there was only a trend towards signifi-
cance in patients receiving the programme in relation to
QoL [55].
The present study will use CAAT-PARK, a manualised
intervention package that aims to ensure people with
PD and their spouse/carers develop a vital understand-
ing of the importance and personal benefit of sound
medication adherence. Unlike previous studies, CAAT-
PARK further recognises the importance of the spouse/
carer for optimising medication adherence. Medication
taking behaviour is a complex phenomenon in PD. A
patient with PD may stop, omit doses, increase or
decrease his or her medication based on the patient’s
perception of his or her own condition, the efficacy of
the treatment, and his or her understanding of the indi-
cation for a particular drug, either accurate or fallacious.
Discontinuing treatment secondary to actual or per-
ceived adverse reactions, medication sparing (fear of
becoming immune to treatment) and fear of long-term
adverse effects of therapy have further been proposed
[21]. Although didactic information has been shown to
be effective we argue the importance of shared decision-
making between patients and professionals, encouraging
a dynamic and reflective process. With CAAT-PARK we
attempt to identify and emphasise the personally rele-
vant benefits to medication, which we argue will lead to
positive behaviour change and resultantly improve medi-
cation adherence.
Study Strengths
Unlike previous studies investigating adherence therapy
programmes, we acknowledge the importance of the
carer in assisting people with PD to take their medica-
tions as prescribed. Due to this dynamic, CAAT-PARK
will be aimed at both the person with PD and their
spouse/carer. The therapy will be delivered in the parti-
cipants’ homes by the same individual (DJD) who has
received specific training in the delivery of CAAT-
PARK. This has a binary affect in that it provides
greater ecological validity and broadens access to the
therapeutic intervention for severely affected PD
patients. Furthermore, the delivery of CAAT-PARK by
one trained clinician eradicates proficiency bias and
ensures standardisation and consistency in the adminis-
tration of the intervention. Although eradication of pro-
ficiency bias may be at the expense of high internal
validity, we have shown the therapy to be effective in
other long-term conditions using various trained
Daley et al. Trials 2011, 12:251
http://www.trialsjournal.com/content/12/1/251
Page 9 of 12
clinicians. We therefore have no reason to believe the
therapeutic intervention lacks validity regarding its
delivery.
Study Limitations
The subjective nature of the self report instruments
used for evaluation of CAAT-PARK is acknowledged
and every effort will be made to minimise this potential
bias. In particular, patients may over or under report
their true health status depending on the trial arm to
which they are assigned. Baseline primary outcome mea-
sures will be completed prior to randomisation in
attempt to reduce this bias. Resulting from the one-to-
one participatory nature of CAAT-PARK, it will not be
possible to mask study participants to their group allo-
cation. Therefore, secondary outcomes at baseline (com-
pleted post randomisation) and all follow-up study
outcomes will not be blinded.
Prognostic Factors
Data from studies have shown cognitive function and
mood to influence medication adherence [56,57]. It has
been previously reported that depressed patients are
considerably more likely to adhere poorly to medication
regimens than non-depressed patients [58]. Depression
has also been shown to negatively affect adherence rates
in PD [23,34]. Cognitive impairment represents a major
risk factor for non-adherence in people with PD [14,59].
Cognitive impairment has further been associated with
under and over-use of medication in PD [14,45,57].
Therefore, it is possible that both cognitive impairment
and the presence of anxiety and depression may deleter-
iously influence the effective uptake of the adherence
intervention. We therefore aim to assess for these prog-
nostic factors at baseline. Data collected for participants
with identified cognitive impairment (assessed using the
MoCA) or anxiety and depression (assessed using the
HADS) will be appropriately adjusted using regression
modelling. Where cognitive impairment and anxiety and
depression are present in study participants at baseline
assessment, analyses will be undertaken to assess their
independent impact on the efficacy of CAAT-PARK.
Further, we will examine which aspects of the MoCA, if
any, predict poor medication adherence in the trial
participants.
Conclusion
Addressing issues surrounding non-adherence by pro-
blem solving and discussing concerns about medication
may facilitate optimal symptom management in PD
through greater medication adherence. If CAAT-PARK
demonstrates efficacy for improving medication adher-
ence and QoL in people with PD and their spouse/
carers, health professionals will be able to incorporate
the intervention into their routine practice with minimal
training. As this has yet to be investigated, we intend to
establish the efficacy of this novel intervention for peo-
ple with PD and their spouse/carers in this RCT. This
study will provide new knowledge about the effective-
ness of optimising the efficacy of anti-parkinsonian
agents using a targeted carer assisted adherence therapy
in PD.
Trial Status
Ongoing. At the time of submission patient recruitment
was 16% of the overall target eight weeks post trial com-
mencement. Recruitment rates are on target and will
continue as a rolling process for the full study period.
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